T-Cell Modulation for the Treatment of Chronic Plaque Psoriasis with Efalizumab (Raptiva™): Mechanisms of Action
Psoriasis is a chronic, incurable, auto-immune disorder with cutaneous manifestations. New evidence on the central role of the immune system in the pathogenesis of psoriasis increasingly provides insight into pathogenic steps that can be modulated to provide disease control. Numerous biological ther...
Gespeichert in:
| Veröffentlicht in: | Dermatology (Basel) 2004-01, Vol.208 (4), p.297-306 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 306 |
|---|---|
| container_issue | 4 |
| container_start_page | 297 |
| container_title | Dermatology (Basel) |
| container_volume | 208 |
| creator | Jullien, D. Prinz, J.C. Langley, R.G.B. Caro, I. Dummer, W. Joshi, A. Dedrick, R. Natta, P. |
| description | Psoriasis is a chronic, incurable, auto-immune disorder with cutaneous manifestations. New evidence on the central role of the immune system in the pathogenesis of psoriasis increasingly provides insight into pathogenic steps that can be modulated to provide disease control. Numerous biological therapies are in various stages of clinical development, with expectation of providing enhanced safety and efficacy over currently available psoriasis therapies. Efalizumab, a recombinant humanized monoclonal IgG1 antibody, is a novel targeted T-cell modulator that inhibits multiple steps in the immune cascade that result in the production and maintenance of psoriatic plaques, including initial T-cell activation and T-cell trafficking into sites of inflammation, including psoriatic skin, with subsequent reactivation in these sites. This article reviews the pharmacodynamic, pharmacokinetic and clinical effects observed during phase I, II and III efalizumab trials in patients with moderate to severe chronic plaque psoriasis. |
| doi_str_mv | 10.1159/000077660 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pasca</sourceid><recordid>TN_cdi_proquest_miscellaneous_20919366</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71980456</sourcerecordid><originalsourceid>FETCH-LOGICAL-c424t-8524727674bc5388bdaa3c6374bbadc1441a97c4fa766c178d32191984d3f68e3</originalsourceid><addsrcrecordid>eNqF0U9rFDEYBvAgFvtHD54FCYVKexjNm8kkmd7K0mqhxSLb8_BOJuOmzky2yUyLnv0k_Wh-ErPs0hYv5pIEfjzJw0vIW2AfAYryE0tLKSnZC7IDgkNW6py_TGcGOtNSFttkN8abpLhW5SuyDQUoXQLskDDPZrbr6KVvpg5H5wfa-kDHhaXzYHHs7TBS39LZIvjBGXrV4e1k6VX0wWF0kd67cUFPW-zcr6nHmh5-w-Xo7vDP74ejY3ppzQIHF_u4Cjkxqwdek63Eo32z2ffI9dnpfPYlu_j6-Xx2cpEZwcWY6YILxZVUojZFrnXdIOZG5uleY2NACMBSGdFiam5SnybnUEKpRZO3Utt8j3xY5y6DT3-OY9W7aFJZHKyfYqWSZaKQ_4WcpdhcruD-P_DGT2FIJSpeACjFuEjoaI1M8DEG21bL4HoMPytg1Wpc1eO4kn2_CZzq3jZPcjOfBA42AKPBrg04GBefOaW1ZGVy79buB4bvNjyC9TN_AUC2pEo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>251177024</pqid></control><display><type>article</type><title>T-Cell Modulation for the Treatment of Chronic Plaque Psoriasis with Efalizumab (Raptiva™): Mechanisms of Action</title><source>MEDLINE</source><source>Karger Journals</source><creator>Jullien, D. ; Prinz, J.C. ; Langley, R.G.B. ; Caro, I. ; Dummer, W. ; Joshi, A. ; Dedrick, R. ; Natta, P.</creator><creatorcontrib>Jullien, D. ; Prinz, J.C. ; Langley, R.G.B. ; Caro, I. ; Dummer, W. ; Joshi, A. ; Dedrick, R. ; Natta, P.</creatorcontrib><description>Psoriasis is a chronic, incurable, auto-immune disorder with cutaneous manifestations. New evidence on the central role of the immune system in the pathogenesis of psoriasis increasingly provides insight into pathogenic steps that can be modulated to provide disease control. Numerous biological therapies are in various stages of clinical development, with expectation of providing enhanced safety and efficacy over currently available psoriasis therapies. Efalizumab, a recombinant humanized monoclonal IgG1 antibody, is a novel targeted T-cell modulator that inhibits multiple steps in the immune cascade that result in the production and maintenance of psoriatic plaques, including initial T-cell activation and T-cell trafficking into sites of inflammation, including psoriatic skin, with subsequent reactivation in these sites. This article reviews the pharmacodynamic, pharmacokinetic and clinical effects observed during phase I, II and III efalizumab trials in patients with moderate to severe chronic plaque psoriasis.</description><identifier>ISSN: 1018-8665</identifier><identifier>EISSN: 1421-9832</identifier><identifier>DOI: 10.1159/000077660</identifier><identifier>PMID: 15178911</identifier><language>eng</language><publisher>Basel, Switzerland: Karger</publisher><subject>Adjuvants, Immunologic - pharmacology ; Adjuvants, Immunologic - therapeutic use ; Antibodies, Monoclonal - pharmacology ; Antibodies, Monoclonal - therapeutic use ; Biological and medical sciences ; Chronic Disease ; Clinical Trials as Topic ; Comments ; Dermatology ; Drug therapy ; Humans ; Immune system ; Medical sciences ; Psoriasis ; Psoriasis - pathology ; Psoriasis - therapy ; Psoriasis. Parapsoriasis. Lichen ; T cell receptors ; T-Lymphocytes - drug effects ; T-Lymphocytes - immunology</subject><ispartof>Dermatology (Basel), 2004-01, Vol.208 (4), p.297-306</ispartof><rights>2004 S. Karger AG, Basel</rights><rights>2004 INIST-CNRS</rights><rights>Copyright 2004 S. Karger AG, Basel</rights><rights>Copyright (c) 2004 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c424t-8524727674bc5388bdaa3c6374bbadc1441a97c4fa766c178d32191984d3f68e3</citedby><cites>FETCH-LOGICAL-c424t-8524727674bc5388bdaa3c6374bbadc1441a97c4fa766c178d32191984d3f68e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,2430,27929,27930</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15788609$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15178911$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jullien, D.</creatorcontrib><creatorcontrib>Prinz, J.C.</creatorcontrib><creatorcontrib>Langley, R.G.B.</creatorcontrib><creatorcontrib>Caro, I.</creatorcontrib><creatorcontrib>Dummer, W.</creatorcontrib><creatorcontrib>Joshi, A.</creatorcontrib><creatorcontrib>Dedrick, R.</creatorcontrib><creatorcontrib>Natta, P.</creatorcontrib><title>T-Cell Modulation for the Treatment of Chronic Plaque Psoriasis with Efalizumab (Raptiva™): Mechanisms of Action</title><title>Dermatology (Basel)</title><addtitle>Dermatology</addtitle><description>Psoriasis is a chronic, incurable, auto-immune disorder with cutaneous manifestations. New evidence on the central role of the immune system in the pathogenesis of psoriasis increasingly provides insight into pathogenic steps that can be modulated to provide disease control. Numerous biological therapies are in various stages of clinical development, with expectation of providing enhanced safety and efficacy over currently available psoriasis therapies. Efalizumab, a recombinant humanized monoclonal IgG1 antibody, is a novel targeted T-cell modulator that inhibits multiple steps in the immune cascade that result in the production and maintenance of psoriatic plaques, including initial T-cell activation and T-cell trafficking into sites of inflammation, including psoriatic skin, with subsequent reactivation in these sites. This article reviews the pharmacodynamic, pharmacokinetic and clinical effects observed during phase I, II and III efalizumab trials in patients with moderate to severe chronic plaque psoriasis.</description><subject>Adjuvants, Immunologic - pharmacology</subject><subject>Adjuvants, Immunologic - therapeutic use</subject><subject>Antibodies, Monoclonal - pharmacology</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Chronic Disease</subject><subject>Clinical Trials as Topic</subject><subject>Comments</subject><subject>Dermatology</subject><subject>Drug therapy</subject><subject>Humans</subject><subject>Immune system</subject><subject>Medical sciences</subject><subject>Psoriasis</subject><subject>Psoriasis - pathology</subject><subject>Psoriasis - therapy</subject><subject>Psoriasis. Parapsoriasis. Lichen</subject><subject>T cell receptors</subject><subject>T-Lymphocytes - drug effects</subject><subject>T-Lymphocytes - immunology</subject><issn>1018-8665</issn><issn>1421-9832</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqF0U9rFDEYBvAgFvtHD54FCYVKexjNm8kkmd7K0mqhxSLb8_BOJuOmzky2yUyLnv0k_Wh-ErPs0hYv5pIEfjzJw0vIW2AfAYryE0tLKSnZC7IDgkNW6py_TGcGOtNSFttkN8abpLhW5SuyDQUoXQLskDDPZrbr6KVvpg5H5wfa-kDHhaXzYHHs7TBS39LZIvjBGXrV4e1k6VX0wWF0kd67cUFPW-zcr6nHmh5-w-Xo7vDP74ejY3ppzQIHF_u4Cjkxqwdek63Eo32z2ffI9dnpfPYlu_j6-Xx2cpEZwcWY6YILxZVUojZFrnXdIOZG5uleY2NACMBSGdFiam5SnybnUEKpRZO3Utt8j3xY5y6DT3-OY9W7aFJZHKyfYqWSZaKQ_4WcpdhcruD-P_DGT2FIJSpeACjFuEjoaI1M8DEG21bL4HoMPytg1Wpc1eO4kn2_CZzq3jZPcjOfBA42AKPBrg04GBefOaW1ZGVy79buB4bvNjyC9TN_AUC2pEo</recordid><startdate>20040101</startdate><enddate>20040101</enddate><creator>Jullien, D.</creator><creator>Prinz, J.C.</creator><creator>Langley, R.G.B.</creator><creator>Caro, I.</creator><creator>Dummer, W.</creator><creator>Joshi, A.</creator><creator>Dedrick, R.</creator><creator>Natta, P.</creator><general>Karger</general><general>S. Karger AG</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7U7</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20040101</creationdate><title>T-Cell Modulation for the Treatment of Chronic Plaque Psoriasis with Efalizumab (Raptiva™): Mechanisms of Action</title><author>Jullien, D. ; Prinz, J.C. ; Langley, R.G.B. ; Caro, I. ; Dummer, W. ; Joshi, A. ; Dedrick, R. ; Natta, P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c424t-8524727674bc5388bdaa3c6374bbadc1441a97c4fa766c178d32191984d3f68e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adjuvants, Immunologic - pharmacology</topic><topic>Adjuvants, Immunologic - therapeutic use</topic><topic>Antibodies, Monoclonal - pharmacology</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Chronic Disease</topic><topic>Clinical Trials as Topic</topic><topic>Comments</topic><topic>Dermatology</topic><topic>Drug therapy</topic><topic>Humans</topic><topic>Immune system</topic><topic>Medical sciences</topic><topic>Psoriasis</topic><topic>Psoriasis - pathology</topic><topic>Psoriasis - therapy</topic><topic>Psoriasis. Parapsoriasis. Lichen</topic><topic>T cell receptors</topic><topic>T-Lymphocytes - drug effects</topic><topic>T-Lymphocytes - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jullien, D.</creatorcontrib><creatorcontrib>Prinz, J.C.</creatorcontrib><creatorcontrib>Langley, R.G.B.</creatorcontrib><creatorcontrib>Caro, I.</creatorcontrib><creatorcontrib>Dummer, W.</creatorcontrib><creatorcontrib>Joshi, A.</creatorcontrib><creatorcontrib>Dedrick, R.</creatorcontrib><creatorcontrib>Natta, P.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Toxicology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Dermatology (Basel)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jullien, D.</au><au>Prinz, J.C.</au><au>Langley, R.G.B.</au><au>Caro, I.</au><au>Dummer, W.</au><au>Joshi, A.</au><au>Dedrick, R.</au><au>Natta, P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>T-Cell Modulation for the Treatment of Chronic Plaque Psoriasis with Efalizumab (Raptiva™): Mechanisms of Action</atitle><jtitle>Dermatology (Basel)</jtitle><addtitle>Dermatology</addtitle><date>2004-01-01</date><risdate>2004</risdate><volume>208</volume><issue>4</issue><spage>297</spage><epage>306</epage><pages>297-306</pages><issn>1018-8665</issn><eissn>1421-9832</eissn><abstract>Psoriasis is a chronic, incurable, auto-immune disorder with cutaneous manifestations. New evidence on the central role of the immune system in the pathogenesis of psoriasis increasingly provides insight into pathogenic steps that can be modulated to provide disease control. Numerous biological therapies are in various stages of clinical development, with expectation of providing enhanced safety and efficacy over currently available psoriasis therapies. Efalizumab, a recombinant humanized monoclonal IgG1 antibody, is a novel targeted T-cell modulator that inhibits multiple steps in the immune cascade that result in the production and maintenance of psoriatic plaques, including initial T-cell activation and T-cell trafficking into sites of inflammation, including psoriatic skin, with subsequent reactivation in these sites. This article reviews the pharmacodynamic, pharmacokinetic and clinical effects observed during phase I, II and III efalizumab trials in patients with moderate to severe chronic plaque psoriasis.</abstract><cop>Basel, Switzerland</cop><pub>Karger</pub><pmid>15178911</pmid><doi>10.1159/000077660</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1018-8665 |
| ispartof | Dermatology (Basel), 2004-01, Vol.208 (4), p.297-306 |
| issn | 1018-8665 1421-9832 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_20919366 |
| source | MEDLINE; Karger Journals |
| subjects | Adjuvants, Immunologic - pharmacology Adjuvants, Immunologic - therapeutic use Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal - therapeutic use Biological and medical sciences Chronic Disease Clinical Trials as Topic Comments Dermatology Drug therapy Humans Immune system Medical sciences Psoriasis Psoriasis - pathology Psoriasis - therapy Psoriasis. Parapsoriasis. Lichen T cell receptors T-Lymphocytes - drug effects T-Lymphocytes - immunology |
| title | T-Cell Modulation for the Treatment of Chronic Plaque Psoriasis with Efalizumab (Raptiva™): Mechanisms of Action |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T00%3A29%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=T-Cell%20Modulation%20for%20the%20Treatment%20of%20Chronic%20Plaque%20Psoriasis%20with%20Efalizumab%20(Raptiva%E2%84%A2):%20Mechanisms%20of%20Action&rft.jtitle=Dermatology%20(Basel)&rft.au=Jullien,%20D.&rft.date=2004-01-01&rft.volume=208&rft.issue=4&rft.spage=297&rft.epage=306&rft.pages=297-306&rft.issn=1018-8665&rft.eissn=1421-9832&rft_id=info:doi/10.1159/000077660&rft_dat=%3Cproquest_pasca%3E71980456%3C/proquest_pasca%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=251177024&rft_id=info:pmid/15178911&rfr_iscdi=true |